SCHEMBL4833465

SCHEMBL4833465

CCOP(=O)(OCC)C(OC)c1ccc(NC(=O)/C=C/c2cnn(C)c2-c2ccc(F)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
KDM4E B2RXH2 3/20 0.37
CCNC P24863 4/20 0.36
CDK8 P49336 4/20 0.36
CDK19 Q9BWU1 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833471 1.00 LMNA (0.38) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL4829459 0.90 ALDH1A1 (0.39) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL4829464 0.90 ALDH1A1 (0.39) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL4825836 0.89 RAB9A (0.40) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL4825813 0.89 RAB9A (0.40) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL4825720 0.85 NPC1 (0.39) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL4825717 0.85 NPC1 (0.39) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL1060125 0.83 BTK (0.41) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL4829084 0.83 BTK (0.41) LMNANPC1RAB9ASMN1; SMN2HTR2A
SCHEMBL4834135 0.81 CCNC (0.44) LMNANPC1RAB9ASMN1; SMN2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 LMNA 2405/4885NPC1 1170/4885RAB9A 4059/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 LMNA 2405/4885NPC1 1170/4885RAB9A 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.